---
document_datetime: 2025-12-02 04:55:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/velcade.html
document_name: velcade.html
version: success
processing_time: 0.14127
conversion_datetime: 2025-12-24 03:12:11.852759
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Velcade

[RSS](/en/individual-human-medicine.xml/65675)

##### Authorised

This medicine is authorised for use in the European Union

bortezomib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Velcade](#news-on)
- [More information on Velcade](#more-information-on-velcade-1048)
- [Preventing medication errors](#preventing-medication-errors-1049)
- [More information on Velcade](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Velcade is a cancer medicine that is generally used in combination with other medicines to treat multiple myeloma, a blood cancer, in:

- adults whose disease is getting worse after at least one other treatment and who have already had blood stem-cell transplantation or cannot have it. In these patients, Velcade is used either on its own or with pegylated liposomal doxorubicin or dexamethasone;
- previously untreated adults who cannot have high-dose chemotherapy with blood stem-cell transplantation. In these patients, Velcade is used in combination with melphalan and prednisone;
- previously untreated adults who are going to receive high-dose chemotherapy followed by a blood stem-cell transplantation. In these patients, Velcade is used in combination with dexamethasone, or with dexamethasone plus thalidomide.

Velcade is also used to treat mantle cell lymphoma, another blood cancer. It is used in adults who have not received any treatment for their cancer and who cannot have blood stem-cell transplantation. In these patients Velcade is used with rituximab, cyclophosphamide, doxorubicin and prednisone.

Velcade contains the active substance bortezomib.

Expand section

Collapse section

## How is Velcade used?

Velcade can only be obtained with a prescription. Treatment should only be started under the supervision of a doctor who has experience in the use of cancer chemotherapy. Velcade is available as an injection containing 1 or 3.5 mg.

Velcade is given by injection into a vein. Velcade 3.5 mg can also be given by injection under the skin in the thigh or the belly. Velcade must not be given in other way. It is given in treatment cycles of 3 to 6 weeks depending on whether Velcade is given alone or in combination with other medicines. The dose depends on the patient's height and weight.

If the patient develops severe side effects, the doctor may reduce the dose, delay the treatment or stop it altogether.

For more information about using Velcade, see the package leaflet or contact your doctor or pharmacist.

## How does Velcade work?

The active substance in Velcade, bortezomib, is a proteasome inhibitor. It blocks the proteasome, which is a system in cells that breaks down proteins that are no longer needed. Blocking the proteasome system results in a build-up of unwanted proteins that causes the cells to die. Proteasome inhibitors have a bigger effect on cancer cells than on normal cells.

## What benefits of Velcade have been shown in studies?

In multiple myeloma, 10 main studies, involving over 4,300 adults, found Velcade given alone or in combination with other medicines to be effective in several patient groups. The main measures of effectiveness were the number of patients whose disease responded to treatment and how long the patients lived without their disease getting worse.

In mantle cell lymphoma, a main study involved 487 previously untreated adults who were not suitable for blood stem-cell transplantation. Patients treated with Velcade together with rituximab, cyclophosphamide, doxorubicin and prednisone lived for 24.7 months without their disease getting worse compared with 14.4 months for patients treated with the same combination but using another medicine, vincristine, in place of Velcade.

## What are the risks associated with Velcade?

The most common side effects with Velcade (which may affect more than 1 in 10 people) are nausea (feeling sick), diarrhoea, constipation, vomiting, tiredness, weakness, fever, thrombocytopenia (low blood platelet count which can lead to easy bruising and bleeding), anaemia (low red blood cell count), neutropenia (low levels of a type of white blood cell that fights infection), nerve damage in arms and legs, headache, paraesthesia (numbness and tingling), decreased appetite, difficulty breathing, rash, shingles, and muscle and bone pain.

The most serious side effects include heart failure, tumour lysis syndrome (complications due to sudden breakdown of cancer cells), pulmonary hypertension (high blood pressure in the arteries of the lungs), posterior reversible encephalopathy syndrome (a brain disorder), acute diffuse infiltrative pulmonary disease (a severe lung problem) and autonomic neuropathy (damage to nerves controlling organs such as the bladder, eyes, gut, heart and blood vessels).

Velcade must not be used in patients who are hypersensitive (allergic) to bortezomib, boron or to any of the other ingredients. It must not be given to patients with acute diffuse infiltrative pulmonary disease or pericardial disease (disease of the sac around the heart).

For the full list of side effects and restrictions of Velcade, see the package leaflet.

## Why is Velcade authorised in the EU?

The European Medicines Agency decided that Velcade's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Velcade?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Velcade have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Velcade are continuously monitored. Side effects reported with Velcade are carefully evaluated and any necessary action taken to protect patients.

## Other information about Velcade

Velcade received a marketing authorisation valid throughout the EU on 26 April 2004.

Velcade : EPAR - Medicine overview

Reference Number: EMA/318389/2020

English (EN) (188.58 KB - PDF)

**First published:** 16/04/2009

**Last updated:** 12/06/2020

[View](/en/documents/overview/velcade-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-790)

български (BG) (222.59 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/bg/documents/overview/velcade-epar-medicine-overview_bg.pdf)

español (ES) (179.92 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/es/documents/overview/velcade-epar-medicine-overview_es.pdf)

čeština (CS) (201.66 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/cs/documents/overview/velcade-epar-medicine-overview_cs.pdf)

dansk (DA) (177.38 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/da/documents/overview/velcade-epar-medicine-overview_da.pdf)

Deutsch (DE) (181.38 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/de/documents/overview/velcade-epar-medicine-overview_de.pdf)

eesti keel (ET) (166.26 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/et/documents/overview/velcade-epar-medicine-overview_et.pdf)

ελληνικά (EL) (220.97 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/el/documents/overview/velcade-epar-medicine-overview_el.pdf)

français (FR) (180.64 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/fr/documents/overview/velcade-epar-medicine-overview_fr.pdf)

hrvatski (HR) (201.17 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/hr/documents/overview/velcade-epar-medicine-overview_hr.pdf)

italiano (IT) (177.77 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/it/documents/overview/velcade-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (208.96 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/lv/documents/overview/velcade-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (201.94 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/lt/documents/overview/velcade-epar-medicine-overview_lt.pdf)

magyar (HU) (200.54 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/hu/documents/overview/velcade-epar-medicine-overview_hu.pdf)

Malti (MT) (229.73 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/mt/documents/overview/velcade-epar-medicine-overview_mt.pdf)

Nederlands (NL) (177.02 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/nl/documents/overview/velcade-epar-medicine-overview_nl.pdf)

polski (PL) (203.86 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/pl/documents/overview/velcade-epar-medicine-overview_pl.pdf)

português (PT) (180.29 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/pt/documents/overview/velcade-epar-medicine-overview_pt.pdf)

română (RO) (199.97 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/ro/documents/overview/velcade-epar-medicine-overview_ro.pdf)

slovenčina (SK) (202.46 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/sk/documents/overview/velcade-epar-medicine-overview_sk.pdf)

slovenščina (SL) (198.97 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/sl/documents/overview/velcade-epar-medicine-overview_sl.pdf)

Suomi (FI) (176.28 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/fi/documents/overview/velcade-epar-medicine-overview_fi.pdf)

svenska (SV) (176.93 KB - PDF)

**First published:**

16/04/2009

**Last updated:**

12/06/2020

[View](/sv/documents/overview/velcade-epar-medicine-overview_sv.pdf)

Velcade : EPAR - Risk-management-plan summary

English (EN) (72.77 KB - PDF)

**First published:** 08/04/2020

[View](/en/documents/rmp-summary/velcade-epar-risk-management-plan-summary_en.pdf)

## Product information

Velcade : EPAR - Product Information

English (EN) (566.19 KB - PDF)

**First published:** 02/12/2009

**Last updated:** 18/10/2024

[View](/en/documents/product-information/velcade-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-586)

български (BG) (620.72 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/bg/documents/product-information/velcade-epar-product-information_bg.pdf)

español (ES) (571.68 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/es/documents/product-information/velcade-epar-product-information_es.pdf)

čeština (CS) (634.11 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/cs/documents/product-information/velcade-epar-product-information_cs.pdf)

dansk (DA) (594.54 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/da/documents/product-information/velcade-epar-product-information_da.pdf)

Deutsch (DE) (653.11 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/de/documents/product-information/velcade-epar-product-information_de.pdf)

eesti keel (ET) (557.23 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/et/documents/product-information/velcade-epar-product-information_et.pdf)

ελληνικά (EL) (651.08 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/el/documents/product-information/velcade-epar-product-information_el.pdf)

français (FR) (573.42 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/fr/documents/product-information/velcade-epar-product-information_fr.pdf)

hrvatski (HR) (614.77 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/hr/documents/product-information/velcade-epar-product-information_hr.pdf)

íslenska (IS) (595.15 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/is/documents/product-information/velcade-epar-product-information_is.pdf)

italiano (IT) (562.55 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/it/documents/product-information/velcade-epar-product-information_it.pdf)

latviešu valoda (LV) (556.21 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/lv/documents/product-information/velcade-epar-product-information_lv.pdf)

lietuvių kalba (LT) (620.56 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/lt/documents/product-information/velcade-epar-product-information_lt.pdf)

magyar (HU) (603.71 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/hu/documents/product-information/velcade-epar-product-information_hu.pdf)

Malti (MT) (755.92 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/mt/documents/product-information/velcade-epar-product-information_mt.pdf)

Nederlands (NL) (615.04 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/nl/documents/product-information/velcade-epar-product-information_nl.pdf)

norsk (NO) (596.01 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/no/documents/product-information/velcade-epar-product-information_no.pdf)

polski (PL) (618.6 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/pl/documents/product-information/velcade-epar-product-information_pl.pdf)

português (PT) (593.92 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/pt/documents/product-information/velcade-epar-product-information_pt.pdf)

română (RO) (612.04 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/ro/documents/product-information/velcade-epar-product-information_ro.pdf)

slovenčina (SK) (622.82 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/sk/documents/product-information/velcade-epar-product-information_sk.pdf)

slovenščina (SL) (588.86 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/sl/documents/product-information/velcade-epar-product-information_sl.pdf)

Suomi (FI) (603.14 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/fi/documents/product-information/velcade-epar-product-information_fi.pdf)

svenska (SV) (573 KB - PDF)

**First published:**

02/12/2009

**Last updated:**

18/10/2024

[View](/sv/documents/product-information/velcade-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0103 16/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Velcade : EPAR - All Authorised presentations

English (EN) (11.77 KB - PDF)

**First published:** 03/06/2008

**Last updated:** 17/10/2012

[View](/en/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-489)

български (BG) (45.73 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/bg/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.35 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/es/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_es.pdf)

čeština (CS) (40.22 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/cs/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (10.78 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/da/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (11.76 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/de/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.23 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/et/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.29 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/el/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_el.pdf)

français (FR) (11.73 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/fr/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (65.22 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/hr/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (10.62 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/is/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_is.pdf)

italiano (IT) (10.83 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/it/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (41.43 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/lv/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (41.07 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/lt/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (23.74 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/hu/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (40.41 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/mt/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (13.79 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/nl/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (10.77 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/no/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_no.pdf)

polski (PL) (41.12 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/pl/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_pl.pdf)

português (PT) (11.17 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/pt/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_pt.pdf)

română (RO) (40.44 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/ro/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (76.69 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/sk/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (23.35 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/sl/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (10.85 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/fi/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (10.8 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

17/10/2012

[View](/sv/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Velcade Active substance bortezomib International non-proprietary name (INN) or common name bortezomib Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L01XG01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Velcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.

Velcade in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high dose chemotherapy with haematopoietic stem cell transplantation.

Velcade in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation.

Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

## Authorisation details

EMA product number EMEA/H/C/000539 Marketing authorisation holder

Janssen-Cilag International NV

Turnhoutseweg, 30

Marketing authorisation issued 26/04/2004 Revision 46

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Velcade : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (293.19 KB - PDF)

**First published:** 02/12/2009

**Last updated:** 18/10/2024

[View](/en/documents/procedural-steps-after/velcade-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Velcade-H-C-PSUSA-00000424-202004 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/122201/2021

English (EN) (129.71 KB - PDF)

**First published:** 01/03/2021

[View](/en/documents/scientific-conclusion/velcade-h-c-psusa-00000424-202004-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Velcade-H-C-PSUSA-00000424-201804 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/169116/2019

English (EN) (66.7 KB - PDF)

**First published:** 28/03/2019

[View](/en/documents/scientific-conclusion/velcade-h-c-psusa-00000424-201804-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Velcade-H-C-539-II-0079 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/419238/2016

English (EN) (2.94 MB - PDF)

**First published:** 20/06/2016

**Last updated:** 20/06/2016

[View](/en/documents/variation-report/velcade-h-c-539-ii-0079-epar-assessment-report-variation_en.pdf)

Velcade-H-C-PSUSA-00000424-201504 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/747320/2015

English (EN) (67.62 KB - PDF)

**First published:** 10/02/2016

**Last updated:** 10/02/2016

[View](/en/documents/scientific-conclusion/velcade-h-c-psusa-00000424-201504-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Velcade-H-C-539-II-0072 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/74029/2015

English (EN) (2.29 MB - PDF)

**First published:** 27/03/2015

**Last updated:** 27/03/2015

[View](/en/documents/variation-report/velcade-h-c-539-ii-0072-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Velcade

Adopted

Reference Number: EMA/CHMP/782879/2014

English (EN) (69.55 KB - PDF)

**First published:** 19/12/2014

**Last updated:** 19/12/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velcade_en.pdf)

Velcade-H-C-539-II-0063-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/775037/2013

English (EN) (1.44 MB - PDF)

**First published:** 19/02/2014

**Last updated:** 19/02/2014

[View](/en/documents/variation-report/velcade-h-c-539-ii-0063-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Velcade

Adopted

Reference Number: EMA/711216/2013

English (EN) (69.2 KB - PDF)

**First published:** 22/11/2013

**Last updated:** 22/11/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velcade_en.pdf-1)

Velcade-H-C-539-II-0059 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/416707/2013

English (EN) (2.26 MB - PDF)

**First published:** 14/08/2013

**Last updated:** 07/12/2016

[View](/en/documents/variation-report/velcade-h-c-539-ii-0059-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Velcade

Adopted

Reference Number: EMA/CHMP/252977/2013

English (EN) (61.56 KB - PDF)

**First published:** 28/06/2013

**Last updated:** 28/06/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velcade_en.pdf-2)

Velcade-H-C-539-X-0047 : EPAR - Assessment Report - Extension

Reference Number: EMA/432973/2012

English (EN) (1.02 MB - PDF)

**First published:** 17/10/2012

**Last updated:** 17/10/2012

[View](/en/documents/variation-report/velcade-h-c-539-x-0047-epar-assessment-report-extension_en.pdf)

Velcade-H-C-539-A20-0056 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/303400/2012

English (EN) (97.53 KB - PDF)

**First published:** 23/08/2012

**Last updated:** 23/08/2012

[View](/en/documents/variation-report/velcade-h-c-539-a20-0056-epar-assessment-report-article-20_en.pdf)

CHMP post-authorisation summary of positive opinion for Velcade

Adopted

Reference Number: EMA/CHMP/384262/2011

English (EN) (78.84 KB - PDF)

**First published:** 27/05/2011

**Last updated:** 27/05/2011

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velcade_en.pdf-0)

Velcade-H-C-539-II-0028 : EPAR - Assessment Report - Variation

English (EN) (347.04 KB - PDF)

**First published:** 10/09/2008

**Last updated:** 10/09/2008

[View](/en/documents/variation-report/velcade-h-c-539-ii-0028-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Velcade on 24 July 2008

Adopted

Reference Number: EMEA/CHMP/382041/2008

English (EN) (32.58 KB - PDF)

**First published:** 24/07/2008

**Last updated:** 24/07/2008

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velcade-24-july-2008_en.pdf)

## Initial marketing authorisation documents

Velcade : EPAR - Scientific Discussion

English (EN) (529.02 KB - PDF)

**First published:** 15/08/2006

**Last updated:** 15/08/2006

[View](/en/documents/scientific-discussion/velcade-epar-scientific-discussion_en.pdf)

Velcade : EPAR - Procedural steps taken before authorisation

English (EN) (88.55 KB - PDF)

**First published:** 15/08/2006

**Last updated:** 15/08/2006

[View](/en/documents/procedural-steps/velcade-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Velcade

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 December 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-december-2014) 19/12/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 November 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-november-2013) 22/11/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2013) 28/06/2013

[Janssen-Cilag International NV withdraws its application for an extension of the indication for Velcade (bortezomib)](/en/news/janssen-cilag-international-nv-withdraws-its-application-extension-indication-velcade-bortezomib) 03/07/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

[European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-final-recommendations-12-centrally-authorised-medicines-manufactured-ben-venue-laboratories) 16/02/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 January 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-january-2012) 20/01/2012

[European Medicines Agency recommends precautionary recall of remaining batch of Vistide manufactured at Ben Venue Laboratories](/en/news/european-medicines-agency-recommends-precautionary-recall-remaining-batch-vistide-manufactured-ben-venue-laboratories) 13/12/2011

[European Medicines Agency gives further interim recommendations on dealing with shortcomings in quality assurance at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-further-interim-recommendations-dealing-shortcomings-quality-assurance-ben-venue-laboratories) 09/12/2011

[European Medicines Agency gives interim recommendations to deal with shortcomings in quality assurance at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-interim-recommendations-deal-shortcomings-quality-assurance-ben-venue-laboratories) 22/11/2011

[European Medicines Agency recommends new contraindication for Velcade (bortezomib)](/en/news/european-medicines-agency-recommends-new-contraindication-velcade-bortezomib) 20/03/2008

#### More information on Velcade

Final recommendations on 12 centrally authorised medicines manufactured at Ben Venue Laboratories

Reference Number: EMA/106872/2012

English (EN) (188.14 KB - PDF)

**First published:** 16/02/2012

**Last updated:** 22/02/2012

[View](/en/documents/medicine-qa/final-recommendations-12-centrally-authorised-medicines-manufactured-ben-venue-laboratories_en.pdf)

Questions and answers on shortcomings in quality assurance at Ben Venue Laboratories

Reference Number: EMA/946321/2011

English (EN) (71.91 KB - PDF)

**First published:** 13/12/2011

**Last updated:** 13/12/2011

[View](/en/documents/medicine-qa/questions-and-answers-shortcomings-quality-assurance-ben-venue-laboratories_en.pdf)

#### Preventing medication errors

Velcade: questions and answers on recommendations to prevent administration errors

Reference Number: EMA/34910/2012

English (EN) (157.13 KB - PDF)

**First published:** 20/01/2012

[View](/en/documents/medication-error/velcade-questions-answers-recommendations-prevent-administration-errors_en.pdf)

#### More information on Velcade

- [Bortezomib - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/bortezomib)
- [Velcade - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/velcade)
- [A retrospective analysis of pre-existing and acquired major adverse cardiovascular events (MACE) in a real world cohort of multiple myeloma (MM) patients treated with proteasome inhibitors - post-authorisation study](https://catalogues.ema.europa.eu/study/35617)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/10/2024

## Share this page

[Back to top](#main-content)